Healthcare and Life Science
From licensing to integration: is decision-making in life sciences moving upstream?
Recent cross-border licensing activity involving China-origin biopharmaceutical assets suggests a subtle but important shift in how global partnerships are being structured. While attention often focuses on total deal value, the more meaningful signal may lie in the underlying terms. ...
BioResource scientific conference returns for 2026
Join us for the fourth edition of the NIHR BioResource Scientific Conference on Wednesday 17th June. ...
PlaqueTec closes $5 million financing
Oversubscribed round backed by existing shareholders Investment will support development of cardiovascular disease database to be used to inform patient stratification and therapeutic development programmesCambridge, UK, 27 April 2026: PlaqueTec, a medtech company pioneering intracorona...
Build your next big, bold and beautiful controlled environment facility with Cleanroom Solutions
Guardtech’s turnkey brand are redefining high-spec cleanroom construction by marrying operational excellence and environmental efficiency with new installation innovation and stunning aesthetics ...
Top 10 Reasons to Host Your Next Conference in Cambridge
If you're searching for a conference venue in Cambridge, you're already onto something special. With world-class facilities, unrivalled heritage, and excellent transport links, Cambridge is fast becoming one of the UK's most sought-after destinations for corporate events, MICE travel, a...
When both sides have rules: What this means for UK–China life sciences collaboration
For UK life sciences businesses engaging with China, the operating environment has become more structured than many still assume. Not because the opportunity has diminished — it has not — but because the conditions for realising it now require a different level of preparation. Understan...
East Anglian Air Ambulance launches £8.2m appeal to build new Cambridge base
Former patients help charity launch appeal as it calls on people and businesses across Cambridgeshire to help protect the future of their local air ambulance. ...
STORM Therapeutics secures $56 million series C financing and doses first patient in phase 2 Sarcoma Trial of STC‑15
The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indicationsFirst‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation16 April 2026, Cambridge, UK: STORM Therapeutics Ltd., the clinical stage company targe...
Atelerix launches STORganoid cryo-free preservation solution for complex 3D cell models
Ambient-temperature preservation solution enables reliable storage and shipment of organoids and spheroids, to support growing adoption of New Approach Methodologies ...
Bridging Cambridge’s MedTech scale-up gap: the missing link between prototype and production
Cambridge leads in early-stage MedTech innovation, but many promising ideas stall when moving from lab prototypes to clinical-ready devices. The core challenge lies in fragmented, early-stage manufacturing and regulatory pathways, often pushing companies to look overseas. This reflects ...